Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on VIRALYTICS LTD. We currently have 6 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
Cavatak combo data at AACR next month
09 Mar 17
Viralytics will present updates on three Phase Ib trials of Cavatak in combination with marketed immune checkpoint inhibitor (ICI) drugs at the AACR conference in the first week of April, including two prestigious podium presentations. The presentations will include preliminary data from the MITCI and CAPRA intralesional injection trials and an update on the Keynote 200 (STORM) IV Cavatak trial. We leave our valuation unchanged at A$385m or A$1.60/share as we await the updates.
Cavatak data continue to impress
21 Nov 16
Viralytics’ Cavatak continues to impress, with a 100% disease control rate in 10 patients (seven objective responses) in combination with Keytruda in the CAPRA Phase Ib study. Furthermore, in the MITCI Phase Ib trial Cavatak, in combination with Yervoy, achieved a 50% response rate in the first 18 patients treated, which is an impressive response rate in a heavily pre-treated population. The encouraging results are a good sign for the ongoing trials of Cavatak and are likely to be of great interest to potential partners. We have increased our anticipated deal value assumptions for Viralytics following recent deals in oncolytic virotherapy, which lifts our valuation to A$385m or A$1.60/share.
Three Cavatak/checkpoint combination trials
10 Jun 16
Additional data presented at ASCO confirm the potential for synergistic combinations of Cavatak with immune checkpoint inhibitor (ICI) drugs to improve the proportion of cancer patients who respond to ICI therapy. Three Phase Ib trials are underway testing Cavatak in combination with Yervoy or Keytruda in melanoma, lung and bladder cancers. Initial data in April showed an impressive 67% response rate in the first six patients in the MITCI study of Cavatak and Yervoy in melanoma. Further updates on MITCI and initial data from the CAPRA trial of Cavatak plus Keytruda could be potential catalysts for the stock in H216. We maintain our valuation of A$272m (A$1.15 per share) ahead of the anticipated newsflow.
Eye-catching MITCI data
05 May 16
Impressive initial results from the MITCI Phase Ib trial suggest that Viralytics could push to the forefront of the crowded field of immune checkpoint inhibitor (ICI) combination therapies. The first six melanoma patients treated with Cavatak in combination with Yervoy (ipilimumab) experienced a higher response rate (67%) and lower serious adverse event rate (9%) than other prominent ICI combination therapies. These encouraging initial data bode well for the ongoing Phase Ib trials of Cavatak in combination with Merck’s Keytruda in melanoma, lung and bladder cancer, and are likely to be of great interest to potential partners. We increase our valuation to A$272m (A$192m previously), or A$1.15 per share (was A$1.04).
Combination trials gather momentum
27 Nov 15
Viralytics is escalating combination trials of its Cavatak oncolytic virotherapy with immune checkpoint inhibitors (ICI), adding a collaboration with Merck to study IV Cavatak combined with Keytruda in advanced lung and bladder cancers to its portfolio of ongoing trials combining intralesional Cavatak with Keytruda or Yervoy in melanoma patients. Cavatak has the potential to markedly improve the proportion of patients who respond to ICI therapy and we expect it to continue to attract attention from big pharma. We value Viralytics at A$192m or A$1.04 per share.
Clinical data package continues to build
13 Aug 15
Clinical data from CALM, STORM and CANON trials presented at scientific conferences further highlight the potential efficacy of CAVATAK (oncolytic virus) against a range of cancers using several delivery approaches. While the evidence of CAVATAK’s efficacy as a single agent continues to build, it is also likely to be attractive to big pharma companies seeking complementary therapies to boost immune responses to their checkpoint inhibitors; a Phase Ib trial in combination with ipilimumab (Yervoy) is already underway. We value Viralytics at A$189m or A$1.03 per share.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.